Avacopan - ChemoCentryx

Drug Profile

Avacopan - ChemoCentryx

Alternative Names: CCX 168

Latest Information Update: 20 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ChemoCentryx
  • Developer ChemoCentryx; Kissei Pharmaceutical; Mario Negri Institute for Pharmacological Research
  • Class Anti-inflammatories; Cyclopentanes; Piperidines; Small molecules
  • Mechanism of Action Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glomerulonephritis; Anti-neutrophil cytoplasmic antibody-associated vasculitis; Microscopic polyangiitis; Wegener's granulomatosis; Haemolytic uraemic syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Anti-neutrophil cytoplasmic antibody-associated vasculitis
  • Phase III Membranoproliferative glomerulonephritis
  • Phase II Haemolytic uraemic syndrome; IgA nephropathy
  • Clinical Phase Unknown Glomerulonephritis
  • No development reported Autoimmune disorders

Most Recent Events

  • 09 Aug 2018 ChemoCentryx completes enrolment in the phase III ADVOCATE trial for ANCA-associated Vasculitis in the US
  • 24 Jun 2018 Biomarkers information updated
  • 13 Jun 2018 Efficacy data from the phase II CLEAR trial in Anti-neutrophil cytoplasmic antibody-associated Vasculitis presented at the 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top